A Phase 3 interventional study of Bimagrumab and Placebo in Sporadic Inclusion Body Myositis, sponsored by Novartis Pharmaceuticals. Completed at 38 sites in 10 countries. Open to participants aged 36 Years and older. Per ClinicalTrials.gov, last updated 2018-03-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 4th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 3, and was the 20th registered.
65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.
Browse Myositis, Inclusion Body studies →4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Myositis International Health & Research Collaborative Alliance Foundation · Sites in United States
Ages 7+
Austin Neuromuscular Center · Sites in United States
Ages 45–75
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 2–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 36 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 9
First in 1990; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.
Median enrollment 24 across the 27 interventional studies, 59 across the 10 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 37 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 6 studies filed under Myositis, Inclusion Body — fewer than ten, so there is no comparison to draw.
2 of the studies in Myositis, Inclusion Body with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05046821University of California, IrvineSporadic Inclusion Body Myositis Natural History Study | 2027-03-31 |
| NCT06479863Austin Neuromuscular CenterEfficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis | 2027-05-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis. The extension study was planned to consist of a Screening epoch (to assess patient eligibility), followed by a Treatment Period 1 epoch (double-blind and placebo-controlled), and a Treatment Period 2 epoch (open-label). A Post-treatment Follow-up (FUP) epoch was also planned for patients who discontinued prematurely. Patients who complete the core study and qualify for this extension study entered Treatment Period 1 and continued on the study drug to which they were randomized in the core study (either to one of the three bimagrumab doses (1 mg/kg, 3 mg/kg, and 10mg/kg) or placebo) during Treatment Period 1. Thus, Treatment Period 1 was double-blind and placebo-controlled. Participants were to continue in Treatment Period 1 until the dose with the best benefit-risk profile was determined from the core study data and selected (duration of Treatment Period 1 was estimated to be between 6 and 8 months). Once the dose with the best benefit-risk profile was selected, all participants (including those who were receiving placebo) were planned to enter Treatment Period 2 and switch to open-label treatment with bimagrumab at the selected dose. The core study has been completed but since the core study did not meet the primary end point (no bimagrumab dose was identified based on the core study efficacy results) the extension study was terminated as per protocol/sponsor's decision; therefore, no patients had entered Treatment Period 2. Instead, all patients were to return for the End of Treatment Period 1 (EOT1) visit at their next scheduled visit. As per protocol, all patients who discontinued study medication during Treatment Period 1 for any reason, including due to the study having been stopped as per protocol/sponsor's decision, were to have entered and complete the 6-month FUP after their EOT1 visit.
Due to the nature of the design of the core and extension studies and termination of study medication in the extension study, the treatment duration for individual patients varied considerably. Consequently, the number of patients contributing data to the efficacy analyses at Week 104 and later timepoints was decreased.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
Drug: Bimagrumab
Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
Drug: Bimagrumab
Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
Drug: Bimagrumab
Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
Drug: Placebo
BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Also known as: BYM338
Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths.
Safety monitoring was conducted throughout the study. AEs starting on or after the day of first administration of extension study drug until last administration of study drug + 56 days are considered. SAEs starting on or after the day of first administration of extension study drug are considered. Deaths which occurred on or after the day of first administration of extension study drug are considered.
Time frame: to end of study (up to 14 months, including the 6-month treatment-free follow-up period)
Change From Core Study Baseline in 6 Minute Walking Distance Test (6MWD)
The 6MWD test measures the distance (in meters) that a participant can walk in a 6 minute time frame. A positive change from baseline indicates improvement. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.
Time frame: Core study baseline, weeks 52, 78, 104, and >=117
Change From Core Study Baseline in Quadriceps Quantitative Muscle Testing (QMT) on the Right Side
Quantitative Muscle Testing (QMT) was used to describe the long-term evolution of quadriceps muscle strength on the right side. The QMT was performed using the same portable fixed dynamometry (PFD) used in the core study. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.
Time frame: Core study baseline, week 52, week 78, week 104 and >=week 117
Change From Core Study Baseline in Sporadic Inclusion Body Myositis (sIBM) Functional Assessment (sIFA) Score
Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.
Time frame: Core study baseline, week 52, week 78, week 104, and >=week 117
Estimated Annual Number of Falls Per Participant Within Treatment Group
Participants documented any fall occurrences in a paper diary during the study.
Time frame: Core baseline to end of extension double-blind treatment (up to a maximum of 32 months)
Change From Core Study Baseline in Short Physical Performance Battery (SPPB) Score
The SPPB evaluated lower extremities function by testing gait speed, ability to keep standing balance and time to rise from a chair five times. The sub-score for each test ranged from 0 to 4. The summary score, which was a summation of scores from the 3 tests, ranged from 0 to 12. An increase in score indicates improvement in physical performance. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.
Time frame: Core study baseline, week 52, week 78, week 104 and >=week 117
Change in Muscles of the Thigh
Magnetic resonance imaging (MRI) was planned to be used to characterize changes in muscles of the thigh in a subset of patients.
Time frame: up to 1 year, up to 2 years
Number of Patients With Anti-BYM338 Antibodies
Investigated the development of immunogenicity against BYM338.
Time frame: end of double-blind treatment (up to 8 months)
Participants entered extension study treatment period after completing the core study and continued on the study drug to which they were randomized in the core study (one of 3 bimagrumab doses (1mg/kg, 3mg/kg or 10mg/kg) or placebo). Participants discontinued from the treatment period were to enter a 6-month, treatment-free Follow-up Period (FUP).
| Milestone | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Started | 53 | 52 | 51 | 55 |
| Full analysis set | 53 | 52 | 51 | 55 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 53 | 52 | 51 | 55 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 50 | 51 | 48 | 55 |
| Milestone | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Started | 41 | 46 | 44 | 47 |
| Completed | 35 | 41 | 34 | 44 |
| Not completed | 6 | 5 | 10 | 3 |
| Withdrew: Death | 1 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 4 | 9 | 2 |
| Withdrew: Technical problems | 0 | 0 | 1 | 0 |
Safety monitoring was conducted throughout the study. AEs starting on or after the day of first administration of extension study drug until last administration of study drug + 56 days are considered. SAEs starting on or after the day of first administration of extension study drug are considered. Deaths which occurred on or after the day of first administration of extension study drug are considered.
| Participants | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Adverse events | 48 | 50 | 44 | 49 |
| Serious adverse events | 12 | 10 | 7 | 8 |
| Deaths | 1 | 1 | 1 | 2 |
The 6MWD test measures the distance (in meters) that a participant can walk in a 6 minute time frame. A positive change from baseline indicates improvement. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.
| meters | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Week 52 (n=53,52,51,54) | 6.88 ± 68.948 | 9.48 ± 81.676 | -14.26 ± 81.029 | -5.98 ± 78.817 |
| Week 78 | -5.25 ± 122.002 | -9.73 ± 68.302 | -18.66 ± 81.536 | -32.78 ± 96.494 |
| Week 104 | -22.68 ± 102.549 | -50.58 ± 118.012 | -25.08 ± 95.737 | -61.30 ± 107.399 |
| >=Week 117 | -206.65 ± 281.923 | -5.0 ± NA | -53.65 ± 114.322 | 31.60 ± NA |
Quantitative Muscle Testing (QMT) was used to describe the long-term evolution of quadriceps muscle strength on the right side. The QMT was performed using the same portable fixed dynamometry (PFD) used in the core study. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.
| newtons | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Week 52 | -6.29 ± 31.121 | -19.70 ± 77.820 | -5.62 ± 32.245 | -14.22 ± 27.577 |
| Week 78 | -9.43 ± 41.285 | -23.76 ± 73.729 | -17.04 ± 25.696 | -21.02 ± 31.391 |
| Week 104 | -11.92 ± 35.243 | -16.99 ± 34.379 | -18.63 ± 37.968 | -21.91 ± 39.985 |
| >=Week 117 | 67.64 ± NA | 33.38 ± NA | -19.36 ± 18.475 | -18.24 ± NA |
Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.
| score on a scale | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Week 52 | -1.34 ± 15.249 | 1.80 ± 11.910 | 3.17 ± 11.380 | 5.16 ± 13.889 |
| Week 78 | -0.27 ± 13.745 | 5.33 ± 13.099 | 6.52 ± 12.918 | 7.41 ± 14.410 |
| Week 104 | 3.54 ± 14.998 | 8.04 ± 16.861 | 5.97 ± 12.849 | 7.39 ± 15.580 |
| >=Week 117 | -16.37 ± 21.857 | 10.91 ± NA | 1.37 ± 17.655 | 6.36 ± NA |
Participants documented any fall occurrences in a paper diary during the study.
| Annual number of falls per participant | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Estimated Annual Number of Falls Per Participant Within Treatment Group | 4.164 | 3.879 | 3.480 | 3.835 |
The SPPB evaluated lower extremities function by testing gait speed, ability to keep standing balance and time to rise from a chair five times. The sub-score for each test ranged from 0 to 4. The summary score, which was a summation of scores from the 3 tests, ranged from 0 to 12. An increase in score indicates improvement in physical performance. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.
| score on a scale | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Week 52 | 0.3 ± 1.73 | 0.2 ± 1.61 | -0.4 ± 1.74 | -0.3 ± 1.31 |
| Week 78 | -0.5 ± 2.58 | -0.1 ± 1.54 | -0.4 ± 1.69 | -0.9 ± 1.92 |
| Week 104 | -1.4 ± 3.29 | -0.9 ± 2.77 | -1.1 ± 2.56 | -1.3 ± 2.35 |
| >=Week 117 | -3.0 ± 4.24 | 0.0 ± NA | 0.3 ± 2.06 | 0.0 ± NA |
Magnetic resonance imaging (MRI) was planned to be used to characterize changes in muscles of the thigh in a subset of patients.
No measurements were reported for this outcome.
Investigated the development of immunogenicity against BYM338.
| Participants | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Number of Patients With Anti-BYM338 Antibodies | 0 | 1 | 0 | 2 |
Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit, up to 14 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYM338/Bimagrumab 10 mg/kg | 1/53 (1.9%) | 12/53 (22.6%) | 40/53 (75.5%) |
| BYM338/Bimagrumab 3 mg/kg | 1/52 (1.9%) | 10/52 (19.2%) | 46/52 (88.5%) |
| BYM338/Bimagrumab 1 mg/kg | 1/51 (2%) | 7/51 (13.7%) | 38/51 (74.5%) |
| Placebo | 2/55 (3.6%) | 8/55 (14.5%) | 43/55 (78.2%) |
| Pooled Active Treatment Groups | 3/156 (1.9%) | 29/156 (18.6%) | 124/156 (79.5%) |
| Event | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo | Pooled Active Treatment Groups |
|---|---|---|---|---|---|
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/53 | 0/52 | 2/51 | 1/55 | 3/156 |
| SepsisInfections and infestations | 1/53 | 0/52 | 0/51 | 2/55 | 1/156 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/53 | 0/52 | 1/51 | 2/55 | 1/156 |
| PneumoniaInfections and infestations | 1/53 | 1/52 | 1/51 | 1/55 | 3/156 |
| UrosepsisInfections and infestations | 0/53 | 0/52 | 1/51 | 0/55 | 1/156 |
| Avulsion fractureInjury, poisoning and procedural complications | 0/53 | 0/52 | 1/51 | 0/55 | 1/156 |
| FallInjury, poisoning and procedural complications | 0/53 | 0/52 | 1/51 | 1/55 | 1/156 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/53 | 0/52 | 1/51 | 0/55 | 1/156 |
| Peripheral venous diseaseVascular disorders | 0/53 | 0/52 | 1/51 | 0/55 | 1/156 |
| Oesophageal achalasiaGastrointestinal disorders | 0/53 | 1/52 | 0/51 | 0/55 | 1/156 |
| Event | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo | Pooled Active Treatment Groups |
|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 30/53 | 36/52 | 30/51 | 34/55 | 96/156 |
| ContusionInjury, poisoning and procedural complications | 9/53 | 7/52 | 12/51 | 8/55 | 28/156 |
| DiarrhoeaGastrointestinal disorders | 9/53 | 5/52 | 9/51 | 5/55 | 23/156 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 4/53 | 8/52 | 3/51 | 1/55 | 15/156 |
| LacerationInjury, poisoning and procedural complications | 1/53 | 7/52 | 4/51 | 6/55 | 12/156 |
| Skin abrasionInjury, poisoning and procedural complications | 6/53 | 7/52 | 4/51 | 5/55 | 17/156 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/53 | 5/52 | 6/51 | 6/55 | 12/156 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/53 | 5/52 | 3/51 | 2/55 | 9/156 |
| Ligament sprainInjury, poisoning and procedural complications | 5/53 | 2/52 | 2/51 | 3/55 | 9/156 |
| HypertensionVascular disorders | 5/53 | 2/52 | 2/51 | 1/55 | 9/156 |
| Age, Continuous(Years) | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 69.2 ± 8.19 | 67.3 ± 9.04 | 70.0 ± 7.69 | 69.9 ± 7.95 | 69.1 ± 8.24 |
| Sex: Female, Male(Participants) | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 18 | 19 | 17 | 19 | 73 |
| Male | 35 | 33 | 34 | 36 | 138 |
Ran from Nov 2015 to primary completion in Aug 2016, 9 months.
Results were first posted in Mar 2018, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab